Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 9, 2015, Pages 1616-1624

  Shiota, Seiji ^a,b   Reddy, Rita ^a   Alsarraj, Abeer ^a,b,c   El Serag, Hashem B ^a,b,c   Graham, David Y ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HSRandD Houston Center of Excellence   (United States)

Author keywords

Bacterial Resistance; Drug; Eradication Therapy; Gastritis

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; TETRACYCLINE; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM DETECTION; BACTERIUM ISOLATE; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; EPSILOMETER TEST; ESOPHAGOGASTRODUODENOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; PATIENT ASSESSMENT; PREVALENCE; RISK FACTOR; STOMACH BIOPSY; UNITED STATES; VETERAN; DRUG EFFECTS; FEMALE; HELICOBACTER INFECTIONS; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INCIDENCE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; UNITED STATES; VETERANS;

EID: 84939567007     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.02.005     Document Type: Article

References (42)

1. Hosking S.W., Chung S.C.S., Yung M.Y., et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet 1994, 343:508-510.
2. Shiota S., Murakami K., Fujioka T., et al. Population-based strategies for Helicobacter pylori-associated disease management: a Japanese perspective. Expert Rev Gastroenterol Hepatol 2010, 4:149-156.
3. Takenaka R., Okada H., Kato J., et al. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment Pharmacol Ther 2007, 25:805-812.
4. Malfertheiner P., Megraud F., O'Morain C.A., et al. Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. Gut 2012, 61:646-664.
5. Fock K.M., Katelaris P., Sugano K., et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009, 24:1587-1600.
6. Chey W.D., Wong B.C. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007, 102:1808-1825.
7. Liang X., Xu X., Zheng Q., et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol 2013, 11:802-807.
8. Graham D.Y., Lu H., Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007, 12:275-278.
9. Asaka M., Kato M., Takahashi S., et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010, 15:1-20.
10. Meyer J.M., Silliman N.P., Wang W., et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002, 136:13-24.
11. Osato M.S., Reddy R., Graham D.Y. Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. Int J Antimicrob Agents 1999, 12:341-347.
12. Osato M.S., Reddy R., Reddy S.G., et al. Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. Int J Antimicrob Agents 2001, 17:39-44.
13. Duck W.M., Sobel J., Pruckler J.M., et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004, 10:1088-1094.
14. Bochenek W.J., Peters S., Fraga P.D., et al. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. Helicobacter 2003, 8:626-642.
15. Moss S.F. How can we rationally select Helicobacter pylori therapy without resistance data?. Clin Gastroenterol Hepatol 2014, 12:1578.
16. Vakil N., Lanza F., Schwartz H., et al. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004, 20:99-107.
17. Laine L., Estrada R., Trujillo M., et al. Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1996, 10:1029-1033.
18. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004, 53:1374-1384.
19. Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 1998, 115:1278-1282.
20. Perez Aldana L., Kato M., Nakagawa S., et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 2002, 7:306-309.
21. Megraud F., Coenen S., Versporten A., et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013, 62:34-42.
22. Grijalva C.G., Nuorti J.P., Griffin M.R. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. JAMA 2009, 302:758-766.
23. Hicks L.A., Chien Y.W., Taylor T.H., et al. Outpatient antibiotic prescribing and nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003. Clin Infect Dis 2011, 53:631-639.
24. Nordenstedt H., Graham D.Y., Kramer J.R., et al. Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol 2013, 108:65-71.
25. Fischbach L.A., Graham D.Y., Kramer J.R., et al. Association between Helicobacter pylori and Barrett's esophagus: a case-control study. Am J Gastroenterol 2014, 109:357-368.
26. Dixon M., Genta R., Yardley J., et al. Classification and grading of gastritis: the updated Sydney System-International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996, 20:1161-1181.
27. Sonnenberg A., Lash R.H., Genta R.M. A national study of Helicobactor pylori infection in gastric biopsy specimens. Gastroenterology 2010, 139:1894-1901. quiz e12.
28. Grad Y.H., Lipsitch M., Aiello A.E. Secular trends in Helicobacter pylori seroprevalence in adults in the United States: evidence for sustained race/ethnic disparities. Am J Epidemiol 2012, 175:54-59.
29. Graham D.Y., Lee Y.C., Wu M.S. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014, 12:177-186. discussion e12-e13.
30. De Francesco V., Giorgio F., Hassan C., et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointest Liver Dis 2010, 19:409-414.
31. McMahon B.J., Hennessy T.W., Bensler J.M., et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003, 139:463-469.
32. Suda K.J., Hicks L.A., Roberts R.M., et al. Trends and seasonal variation in outpatient antibiotic prescription rates in the United States, 2006 to 2010. Antimicrob Agents Chemother 2014, 58:2763-2766.
33. Tveit A.H., Bruce M.G., Bruden D.L., et al. Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska Native persons from 2000 to 2008. J Clin Microbiol 2011, 49:3638-3643.
34. Gisbert J.P., De La Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006, 23:35-44.
35. Gisbert J.P. Second-line rescue therapy of helicobacter pylori infection. Therap Adv Gastroenterol 2009, 2:331-356.
36. Megraud F., Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007, 20:280-322.
37. Rimbara E., Fischbach L.A., Graham D.Y. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol 2011, 8:79-88.
38. Céspedes A., Larson E. Knowledge, attitudes, and practices regarding antibiotic use among Latinos in the United States: review and recommendations. Am J Infect Control 2006, 34:495-502.
39. Pilotto A., Rassu M., Leandro G., et al. Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study-GISU: Interdisciplinary Group for the Study of Ulcer. Dig Liver Dis 2000, 32:763-768.
40. Williams C.S., Woodcock K.R. Do ethanol and metronidazole interact to produce a disulfiram-like reaction?. Ann Pharmacother 2000, 34:255-257.
41. Kirby A., Herbert A. Correlations between income inequality and antimicrobial resistance. PLoS One 2013, 8:e73115.
42. Chen F.M., Breiman R.F., Farley M., et al. Geocoding and linking data from population-based surveillance and the US census to evaluate the impact of median household income on the epidemiology of invasive Streptococcus pneumoniae infections. Am J Epidemiol 1998, 148:1212-1218.